Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
1.
Rev Col Bras Cir ; 50: e20233515, 2023.
Artigo em Inglês, Português | MEDLINE | ID: mdl-37556611

RESUMO

BACKGROUND: the use of nipple-sparing mastectomy (NSM) in local advanced breast cancer after neoadjuvant chemotherapy (NQT) is increasing, despite few studies on the subject. The aim of this systematic review was to determine the safety of NSM after neoadjuvant chemotherapy. METHODS: for this systematic review we searched MEDLINE; Cochrane; Scientific Electronic Library Online (SciELO); Embase and Scopus. A literature search of all original studies including randomized controlled trials, cohort studies and case-control studies comparing women undergoing NSM after neoadjuvant chemotherapy for breast cancer was undertaken. Outcomes were locoregional recurrence (LRR), nipple recurrence and distant recurrence (DR). Data analysis was undertaken to explore the safety of NSM after NQT. The quality of the evidence was assessed with the Cochrane risk of bias tool. This study is registered on PROSPERO, number CRD42021276778. FINDINGS: a total of 437 articles were identified. Four articles were included with 1466 patients all of which had a high to serious risk of overall bias. Local recurrence in the NSM after the NQT group ranged from zero to 9.8%. Nippleareolar complex (NAC) recurrence ranged from zero to 2.1%. The distant recurrence rate ranged from 6.5% to 16%. Due to the lack of pattern among the control groups, it was not possible to perform a meta-analysis. INTERPRETATION: this review provides information for decision making in performing NSM after NQT. Despite the low rates of local recurrence and patients should be counseled about limited oncological information.


Assuntos
Neoplasias da Mama , Humanos , Feminino , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/cirurgia , Mastectomia/efeitos adversos , Terapia Neoadjuvante , Mamilos/cirurgia , Tratamentos com Preservação do Órgão/efeitos adversos , Estudos Retrospectivos , Recidiva Local de Neoplasia/epidemiologia
3.
Rev. Col. Bras. Cir ; 50: e20233515, 2023. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1449178

RESUMO

ABSTRACT Background: the use of nipple-sparing mastectomy (NSM) in local advanced breast cancer after neoadjuvant chemotherapy (NQT) is increasing, despite few studies on the subject. The aim of this systematic review was to determine the safety of NSM after neoadjuvant chemotherapy. Methods: for this systematic review we searched MEDLINE; Cochrane; Scientific Electronic Library Online (SciELO); Embase and Scopus. A literature search of all original studies including randomized controlled trials, cohort studies and case-control studies comparing women undergoing NSM after neoadjuvant chemotherapy for breast cancer was undertaken. Outcomes were locoregional recurrence (LRR), nipple recurrence and distant recurrence (DR). Data analysis was undertaken to explore the safety of NSM after NQT. The quality of the evidence was assessed with the Cochrane risk of bias tool. This study is registered on PROSPERO, number CRD42021276778. Findings: a total of 437 articles were identified. Four articles were included with 1466 patients all of which had a high to serious risk of overall bias. Local recurrence in the NSM after the NQT group ranged from zero to 9.8%. Nippleareolar complex (NAC) recurrence ranged from zero to 2.1%. The distant recurrence rate ranged from 6.5% to 16%. Due to the lack of pattern among the control groups, it was not possible to perform a meta-analysis. Interpretation: this review provides information for decision making in performing NSM after NQT. Despite the low rates of local recurrence and patients should be counseled about limited oncological information.


RESUMO Introdução: O uso de mastectomia preservadora de complexo aréolo-papilar (MPCAP) no câncer de mama localmente avançado após quimioterapia neoadjuvante (QTN) é crescente, apesar de ainda haver poucos estudos abordando o assunto. O objetivo desta revisão sistemática foi determinar a segurança da MPCAP após a quimioterapia neoadjuvante. Métodos: para esta revisão sistemática, pesquisamos no MEDLINE; Cochrane; Scientific Electronic Library Online (SciELO); Embase e Scopus. Foi realizada uma busca na literatura de todos os estudos originais, incluindo ensaios clínicos randomizados, estudos de coorte e estudos de caso-controle comparando mulheres submetidas a MPCAP após quimioterapia neoadjuvante para câncer de mama. Os desfechos foram recorrência locorregional, recidiva em papila e recorrência à distância. A análise dos dados foi realizada para avaliar a segurança da mastectomia preservadora de complexo aréolo-papilar após o QTN. A qualidade da evidência foi avaliada com a ferramenta de avaliação de risco de viés da Cochrane - ROBINS-I. Este estudo está registrado no PROSPERO, número CRD42021276778. Resultados: Um total de 437 artigos foram identificados. Quatro artigos foram incluídos na análise, totalizando 1466 pacientes, todos com risco de viés geral moderado a alto. A recorrência local no grupo MPCAP após QTN variou de zero a 9,8%. A recorrência no complexo aréolo-papilar (CAP) variou de zero a 2,1%. A taxa de recorrência à distância variou de 6,5% a 16%. Devido à falta de padrão entre os grupos de controle, não foi possível realizar uma meta-análise. Interpretação: esta revisão fornece informações para a tomada de decisão na realização de NSM após QTN. Apesar das baixas taxas de recorrência local, os pacientes devem ser orientados sobre as informações oncológicas limitadas.

4.
Rev. bras. hipertens ; 30(3): 78-83, set. 2023. tab
Artigo em Português | LILACS | ID: biblio-1517121

RESUMO

Embora pacientes submetidas ao tratamento cirúrgico para Neoplasia de Mama, de modo geral e frequente, recebam orientações para não medir a pressão arterial no braço homolateral ao seu tratamento, devemos reavaliar contemporaneamente e cientificamente estas recomendações. O propósito deste trabalho é demonstrar os dados de Medicina Baseada em Evidências e considerar a evolução da abordagem cirúrgica neste grupo de pacientes, atualizando estas recomendações e demostram dados de enquete sobre o assunto entre médicos de diferentes especialidades. Há suficiente suporte científico e explicações para que orientemos de forma individualizada e coerentemente estas pacientes em relação a medida da pressão arterial e consequentemente sua relação com o aparecimento do linfedema no braço homolateral, porém a Sociedade Brasileira de Cardiologia, pelo seu Departamento de Hipertensão Arterial não tem recomendações sobre este assunto. Que deve ser contextualizado devido a má percepção sobre o assunto, em repostas a uma enquete feita com Cardiologistas e Mastologistas sobre este tema (AU)


Although patients undergoing surgical treatment for breast cancer are often advised against measuring blood pressure in the arm on the same side as their treatment, it is crucial to reevaluate these recommendations using contemporary and scientific evidence. The objective of this study is to present empirical data on Evidence-Based Medicine and explore the evolving surgical approaches in this patient population. By updating these recommendations and showcasing survey results from physicians across different specialties, we aim to provide comprehensive guidance on the topic. While there is ample scientific support and explanations to individually and coherently guide these patients regarding blood pressure measurement and its potential association with lymphedema in the affected arm, it is important to note that the Brazilian Society of Cardiology, specifically its Department of Arterial Hypertension, does not currently offer recommendations on this matter. This contextualization is necessary due to the limited awareness and understanding of the subject, as revealed through responses obtained from Cardiologists and Mastologists participating in our survey.


Assuntos
Humanos , Feminino , Radioterapia , Hipertensão
5.
Comput Biol Chem ; 100: 107746, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-35961236

RESUMO

Several evidence has demonstrated the involvement of the ribosomal proteins (RPs) in many malignancies, however, the function and clinical relevance of the RPs in breast cancer remains unclear. The present study aims to contribute to the understanding of the role of the RPs in breast tumorigenesis and its clinical implications in the field of biomarker discovery and outcome prediction. We investigated the proteomic and transcriptomic expression of the RPs in non-tumor and tumor tissues of different breast cancer subtypes, and integrated bioinformatics approaches and online databases to comprehensively evaluate the potential functions, regulatory networks, mutational landscape, and prognostic values of the ribosomal proteins in breast cancer. Our results show that 33 RPs have deregulated expression in breast cancer and its subtypes and that 26 RPs have potential as prognostic markers in a subtype-dependent way, with mutations in RP genes being frequent in breast tumors and related to overall survival and relapse-free status. Our RP gene regulatory network indicates the transcription factors MYC, ETS1, and SPI1, and the miRNAs has-let-7c-5p, has-mir-20b-5p, and has-mir-4668-3p as regulators of the RPs expression in breast cancer. The RPs were associated with several clinicopathological parameters of breast cancer and predicted to be involved in ribosomal-independent mechanisms such as regulation of the SLITS-ROBO pathway. This study comprehensively investigated the ribosomal proteins in breast cancer, suggesting that the RPs have clinical potential as biomarkers of diagnostic and prognostic, also providing an in-depth view of the RPs significance in breast cancer.


Assuntos
Neoplasias da Mama , MicroRNAs , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/genética , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , MicroRNAs/genética , Mutação , Prognóstico , Proteômica , Proteínas Ribossômicas/genética , Proteínas Ribossômicas/metabolismo , Transcriptoma
6.
Rev Bras Ginecol Obstet ; 43(9): 690-698, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34670304

RESUMO

OBJECTIVE: Infection and exposure of the implant are some of the most common and concerning complications after implant-based breast reconstruction. Currently, there is no consensus on the management of these complications. The aim of the present study was to review our cases and to present a clinical protocol. METHODS: We conducted a retrospective review of consecutive patients submitted to implant-based breast reconstruction between 2014 and 2016. All patients were managed according to a specific and structured protocol. RESULTS: Implant exposure occurred in 33 out of 277 (11.9%) implant-based reconstructions. Among these, two patients had history of radiotherapy and had their implant removed; Delayed reconstruction with a myocutaneous flap was performed in both cases. Signs of severe local infection were observed in 12 patients, and another 5 presented with extensive tissue necrosis, and they were all submitted to implant removal; of them, 8 underwent reconstruction with a tissue expander, and 2, with a myocutaneous flap. The remaining 14 patients had no signs of severe infection, previous irradiation or extensive tissue necrosis, and were submitted to primary suture as an attempt to salvage the implant. Of these, 8 cases (57.1%) managed to keep the original implant. CONCLUSION: Our clinical protocol is based on three key points: history of radiotherapy, severe infection, and extensive tissue necrosis. It is a practical and potentially-reproducible method of managing one of the most common complications of implant-based breast reconstruction.


OBJECTIVO: Infecção e exposição da prótese são algumas das complicações mais comuns e preocupantes após reconstrução da mama com implantes. Atualmente, ainda não há consenso quanto ao manejo destas complicações. O objetivo deste estudo foi o de revisar os casos da nossa instituição e apresentar um protocolo clínico. MéTODOS: Realizou-se uma revisão retrospectiva de todos os casos consecutivos submetidos a reconstrução mamária imediata com prótese entre 2014 e 2016. Todos os casos foram conduzidos de acordo com um protocolo específico e estruturado. RESULTADOS: A exposição do implante ocorreu em 33 de 227 reconstruções (11,9%). Dentre estas, duas pacientes tinham histórico de radioterapia, e foram submetidas a remoção da prótese e posterior reconstrução com retalho miocutâneo. Sinais de infecção local grave foram observados em 12 pacientes, e, em 5, necrose extensa de tecido, e todas foram submetidas a remoção dos implantes; destas, 8 foram reconstruídas com expansor, e 2, com retalho miocutâneo. As 14 pacientes remanecentes não haviam sido submetidas previamente à radioterapia, não tinham sinais de infecção, nem necrose extensa; portanto, foram submetidas a sutura primária em uma tentativa de salvar a prótese. Dessas, 8 pacientes (57,1%) conseguiram manter os implantes originais. CONCLUSãO: Nosso protocolo clínico é baseado em três pontos principais: histórico de radioterapia, infecção grave, e necrose extensa de tecido. Ele constitui um método prático e potencialmente reprodutível de manejo de uma das complicações mais comuns da reconstrução mamária com implantes.


Assuntos
Implantes de Mama , Neoplasias da Mama , Mamoplastia , Implantes de Mama/efeitos adversos , Neoplasias da Mama/cirurgia , Protocolos Clínicos , Feminino , Humanos , Mamoplastia/efeitos adversos , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/cirurgia , Estudos Retrospectivos , Dispositivos para Expansão de Tecidos/efeitos adversos
7.
Rev. bras. ginecol. obstet ; 43(9): 690-698, Sept. 2021. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1351773

RESUMO

Abstract Objective Infection and exposure of the implant are some of the most common and concerning complications after implant-based breast reconstruction. Currently, there is no consensus on the management of these complications. The aim of the present study was to review our cases and to present a clinical protocol. Methods We conducted a retrospective review of consecutive patients submitted to implant-based breast reconstruction between 2014 and 2016. All patients were managed according to a specific and structured protocol. Results Implant exposure occurred in 33 out of 277 (11.9%) implant-based reconstructions. Among these, two patients had history of radiotherapy and had their implant removed; Delayed reconstruction with a myocutaneous flap was performed in both cases. Signs of severe local infection were observed in 12 patients, and another 5 presented with extensive tissue necrosis, and they were all submitted to implant removal; of them, 8 underwent reconstruction with a tissue expander, and 2, with a myocutaneous flap. The remaining 14 patients had no signs of severe infection, previous irradiation or extensive tissue necrosis, and were submitted to primary suture as an attempt to salvage the implant. Of these, 8 cases (57.1%) managed to keep the Conclusion Our clinical protocol is based on three key points: history of radiotherapy, severe infection, and extensive tissue necrosis. It is a practical and potentially-reproducible method of managing one of the most common complications of implant-based breast reconstruction.


Resumo Objectivo Infecção e exposição da prótese são algumas das complicações mais comuns e preocupantes após reconstrução da mama com implantes. Atualmente, ainda não há consenso quanto ao manejo destas complicações. O objetivo deste estudo foi o de revisar os casos da nossa instituição e apresentar um protocolo clínico. Métodos Realizou-se uma revisão retrospectiva de todos os casos consecutivos submetidos a reconstrução mamária imediata com prótese entre 2014 e 2016. Todos os casos foram conduzidos de acordo com um protocolo específico e estruturado. Resultados A exposição do implante ocorreu em 33 de 227 reconstruções (11,9%). Dentre estas, duas pacientes tinham histórico de radioterapia, e foram submetidas a remoção da prótese e posterior reconstrução com retalho miocutâneo. Sinais de infecção local grave foram observados em 12 pacientes, e, em 5, necrose extensa de tecido, e todas foram submetidas a remoção dos implantes; destas, 8 foram recons truídas com expansor, e 2, com retalho miocutâneo. As 14 pacientes remanecentes não haviam sido submetidas previamente à radioterapia, não tinham sinais de infecção, nem necrose extensa; portanto, foram submetidas a sutura primária em uma tentativa de salvar a prótese. Dessas, 8 pacientes (57,1%) conseguiram manter os implantes originais. Conclusão Nosso protocolo clínico é baseado em três pontos principais: histórico de radioterapia, infecção grave, e necrose extensa de tecido. Ele constitui um método prático e potencialmente reprodutível de manejo de uma das complicações mais comuns da reconstrução mamária com implantes.


Assuntos
Humanos , Feminino , Neoplasias da Mama/cirurgia , Mamoplastia/efeitos adversos , Implantes de Mama/efeitos adversos , Complicações Pós-Operatórias/cirurgia , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/epidemiologia , Dispositivos para Expansão de Tecidos/efeitos adversos , Protocolos Clínicos , Estudos Retrospectivos
8.
Genet Mol Biol ; 44(1): e20190410, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33656060

RESUMO

Male breast cancer (MBC) is a rare malignancy that accounts for about 1.8% of all breast cancer cases. In contrast to the high number of the "omics" studies in breast cancer in women, only recently molecular approaches have been performed in MBC research. High-throughput proteomics based methodologies are promisor strategies to characterize the MBC proteomic signatures and their association with clinico-pathological parameters. In this study, the label-free quantification-mass spectrometry and bioinformatics approaches were applied to analyze the proteomic profiling of a MBC case using the primary breast tumor and the corresponding axillary metastatic lymph nodes and adjacent non-tumor breast tissues. The differentially expressed proteins were identified in the signaling pathways of granzyme B, sirtuins, eIF2, actin cytoskeleton, eNOS, acute phase response and calcium and were connected to the upstream regulators MYC, PI3K SMARCA4 and cancer-related chemical drugs. An additional proteomic comparative analysis was performed with a primary breast tumor of a female patient and revealed an interesting set of proteins, which were mainly involved in cancer biology. Together, our data provide a relevant data source for the MBC research that can help the therapeutic strategies for its management.

9.
Genet Mol Biol ; 44(1): e20200216, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33721012

RESUMO

Breast cancer (BC) is the leading cause of death by this disease in women worldwide. Among the factors involved in tumorigenesis, long non-coding RNAs (lncRNAs) and their differential expression have been associated. Differences in gene expression may be triggered by variations in DNA sequence, including single nucleotide polymorphisms (SNPs). In the present study, we analyzed the rs527616 (C>G), located in the lncRNA AQP4-AS1, using PCR-SSP in 306 BC patients and 312 controls, from a Brazilian population. In the BC group, the frequency found for CG heterozygotes was above the expected and the overdominant model is the best one to explain our results (OR: 1.70, IC 95%: 1.23-2.34, P<0.001). Furthermore, the SNP were associated with age at BC diagnosis and the risk genotype more frequent in the older age group. According to TCGA data, AQP4-AS1 is down-regulated in BC tissue, and the overexpression is associated with better prognoses, including Luminal A, HER2-, stage 1 of disease and smaller tumor. In conclusion, the CG genotype is associated with increased susceptibility in the southern Brazilian population. This SNP is mapped in the lncRNA AQP4-AS1, showing differential expression in BC samples. Based on these results, we emphasize the potential of the role of AQP4-AS1 in cancer.

10.
Genet Mol Biol ; 42(4): e20190278, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32142098

RESUMO

MicroRNAs (miRNAs) play an essential role in gene expression and affect the development of tumours, including breast cancer (BC). Polymorphisms in miRNA genes can affect the interaction of miRNAs with their target messenger RNA by interfering, creating or disrupting target sites. The single nucleotide polymorphism (SNP) rs2910164, located in the seed region of miR146a, was shown to be associated with BC among different populations. In the present study, we investigated whether rs2910164 is associated with BC in 326 patients and 411 controls from a Brazilian population of predominantly European ancestry. The presence of the allele rs2910164*C was associated with an increased risk of BC (OR=1.4, 95% CI=1.03-1.85, p = 0.03). We also analysed publicly available RNA-seq data to evaluate if miR146a is differentially expressed in different subtypes of BC. Genotyping was performed by polymerase chain reaction with sequence-specific primers (PCR-SSP). By leveraging public data from TCGA database, we analysed 461 patients and found that miR146a is significantly more expressed in BC than in non-tumor tissue (1.47 fold, p = 0.02) and is expressed to a greater degree in aggressive BC subtypes.

11.
Biomolecules ; 10(1)2020 01 16.
Artigo em Inglês | MEDLINE | ID: mdl-31963351

RESUMO

MicroRNAs derived from extracellular vesicles (EV-miRNAs) are circulating miRNAs considered as potential new diagnostic markers for cancer that can be easily detected in liquid biopsies. In this study, we performed RNA sequencing analysis as a screening strategy to identify EV-miRNAs derived from serum of clinically well-annotated breast cancer (BC) patients from the south of Brazil. EVs from three groups of samples (healthy controls (CT), luminal A (LA), and triple-negative (TNBC)) were isolated from serum using a precipitation method and analyzed by RNA-seq (screening phase). Subsequently, four EV-miRNAs (miR-142-5p, miR-150-5p, miR-320a, and miR-4433b-5p) were selected to be quantified by quantitative real-time PCR (RT-qPCR) in individual samples (test phase). A panel composed of miR-142-5p, miR-320a, and miR-4433b-5p distinguished BC patients from CT with an area under the curve (AUC) of 0.8387 (93.33% sensitivity, 68.75% specificity). The combination of miR-142-5p and miR-320a distinguished LA patients from CT with an AUC of 0.9410 (100% sensitivity, 93.80% specificity). Interestingly, decreased expression of miR-142-5p and miR-150-5p were significantly associated with more advanced tumor grades (grade III), while the decreased expression of miR-142-5p and miR-320a was associated with a larger tumor size. These results provide insights into the potential application of EVs-miRNAs from serum as novel specific markers for early diagnosis of BC.


Assuntos
Neoplasias da Mama/genética , Vesículas Extracelulares/genética , Regulação Neoplásica da Expressão Gênica , MicroRNAs/genética , Adulto , Idoso , Biomarcadores Tumorais/sangue , Biomarcadores Tumorais/genética , Neoplasias da Mama/sangue , Feminino , Perfilação da Expressão Gênica , Humanos , MicroRNAs/sangue , Pessoa de Meia-Idade , Neoplasias de Mama Triplo Negativas/sangue , Neoplasias de Mama Triplo Negativas/genética
12.
Data Brief ; 25: 104125, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31294064

RESUMO

Data present here describe a comparative proteomic analysis among the malignant [primary breast tumor (PT) and axillary metastatic lymph nodes (LN)], and the non-tumor [contralateral (NCT) and adjacent (ANT)] breast tissues. Protein identification and quantification were performed through label-free mass spectrometry using a nano-liquid chromatography coupled to an electrospray ionization-mass spectrometry (nLC-ESI-MS/MS). The mass spectrometry proteomic data have been deposited to the ProteomeXchange Consortium via PRIDE partner repository with the dataset identifier PXD012431. A total of 462 differentially expressed proteins was identified among these tissues and was analyzed in six groups' comparisons (named NCTxANT, PTxNCT, PTxANT, LNxNCT, LNxANT and PTxLN). Proteins at 1.5 log2 fold change were submitted to the Ingenuity® Pathway Analysis (IPA) software version 2.3 (QIAGEN Inc.) to identify biological pathways, disease and function annotation, and interaction networks related to cancer biology. The detailed data present here provides information about the proteome alterations and their role on breast tumorigenesis. This information can lead to novel biological insights on cancer research. For further interpretation of these data, please see our research article 'Quantitative label-free mass spectrometry using contralateral and adjacent breast tissues reveal differentially expressed proteins and their predicted impacts on pathways and cellular functions in breast cancer' [2].

13.
Eur J Histochem ; 62(3)2018 Sep 03.
Artigo em Inglês | MEDLINE | ID: mdl-30362671

RESUMO

Breast cancer is a very heterogeneous disease. The intrinsic molecular subtypes can explain the intertumoral heterogeneity and the cancer stem cell (CSC) hypothesis can explain the intratumoral heterogeneity of this kind of tumor. CD44+/CD24- phenotype and ALDH1 expression are the major CSC markers described in invasive breast cancer. In the present study, 144 samples of invasive breast carcinoma, no special type were distributed in 15 tissue microarrays (TMA) and then evaluated for expression of the CD44+/CD24- phenotype and ALDH1 to understand the importance of these CSC markers and the clinical aspects of breast cancer. The samples were classified into four molecular subtypes according to clinicopathological criteria: Luminal A, Luminal B, HER2, and Basal-like. A statistical association was found between the molecular subtypes and the CSC markers, with HER2 the most frequent subtype for both markers. ALDH1 was also associated with other poor prognostic variables, such as a high histological grade and larger tumors, but it was not associated with the patients' prognosis in this sample and nor was the CD44+/CD24- phenotype in a multivariate analysis. There are still many controversies about the role of these markers in breast cancer molecular subtypes. The identification of these populations of cells, through immunohistochemical markers, can help to better understand the CSC theory in clinical practice and, in the near future, contribute to developing new target therapies.


Assuntos
Biomarcadores Tumorais/química , Antígeno CD24/sangue , Carcinoma Ductal de Mama/classificação , Carcinoma Ductal de Mama/diagnóstico , Receptores de Hialuronatos/sangue , Isoenzimas/química , Metástase Linfática/patologia , Retinal Desidrogenase/química , Adulto , Idoso , Idoso de 80 Anos ou mais , Família Aldeído Desidrogenase 1 , Feminino , Humanos , Imuno-Histoquímica , Pessoa de Meia-Idade , Análise Multivariada , Fenótipo , Prognóstico
14.
Mastology (Impr.) ; 28(2): 125-130, abr.-jun.2018.
Artigo em Inglês | LILACS | ID: biblio-965420

RESUMO

Introduction: Nipple-sparing mastectomy (NSM) and preservation of the nipple-areola complex (NAC) represent a therapeutic option of breast cancer with a better aesthetic result, a positive impact on body image and more satisfaction than the reconstruction of the NAC. It is questioned the indication of radiotherapy when the NAC is maintained and its potential aesthetic impairment. Objective: To examine the indication of radiotherapy in NSM and, secondarily, the incidence of NAC involvement and local recurrence rates. Methods: Systematic review carried out in the PubMed database with the terms ("breast neoplasm" [Mesh] OR "breast cancer") AND ("radiotherapy" OR "radiation therapy") AND ("nipple sparing mastectomy" OR "mastectomies" OR "subcutaneous mastectomies"). The selection of the studies, the evaluation of its quality and data extraction were carried out independently by four reviewers. Results: The indications for radiotherapy after NSM were: positive axilla, tumors over 5 cm and retroareolar tissue remaining greater than 5 mm. The NAC involvement occurred in 5 to 26.1% in the definitive anatomopathological study. NAC recurrence occurred from 2.59 to 10%. NAC necrosis occurred in 2.2 to 43.4%. Conclusions: The radiotherapy indications for NSM seem to follow the same classical indications for radiotherapy after mastectomy. The relapse index in NAC was not shown to be larger and without difference for the type of radiotherapy used. Radiotherapy should be based on factors that suggest a high risk for NAC involvement


Introdução: A mastectomia nipple-sparing (MNS) e a conservação do complexo aréolo-papilar (CAP) representam uma manobra terapêutica do câncer de mama com melhor resultado estético, impacto positivo na imagem corporal e mais satisfação do que a reconstrução do CAP. Questiona-se a indicação de radioterapia quando da manutenção do CAP e seu potencial prejuízo estético. Objetivo: Examinar a indicação de radioterapia em MNS e, secundariamente, a incidência do envolvimento do CAP e as taxas de recorrência local. Métodos: Revisão sistemática realizada na base de dados do PubMed com os termos ("breast neoplasm" [Mesh] OR "breast cancer") AND ("radiotherapy" OR "radiation therapy") AND ("nipple sparing mastectomy" OR "mastectomies" OR "subcutaneous mastectomies"). A seleção dos estudos, a avaliação da qualidade do estudo e a extração de dados foram realizadas de forma independente por quatro revisores. Resultados: As indicações para radioterapia após MNS foram: axila positiva, tumores acima de 5 cm e tecido retroareolar remanescente maior que 5 mm. O envolvimento do CAP ocorreu em 5 a 26,1% no anatomopatológico definitivo. A recorrência no CAP ocorreu de 2,59 a 10%. A necrose do CAP ocorreu em 2,2 a 43,4%. Conclusão: As indicações de radioterapia para MNS parecem seguir as mesmas indicações clássicas para radioterapia após mastectomia. O índice de recidiva no CAP não mostrou ser maior com uso de radioterapia nem ter diferença quanto ao seu tipo. A decisão de realizar a radioterapia deve se basear em fatores que sugerem alto risco para envolvimento do CAP

15.
Mastology (Impr.) ; 27(4): 324-333, oct.-dez.2017.
Artigo em Inglês | LILACS | ID: biblio-884313

RESUMO

Objective: This study aims to investigate the efficacy and improvement of knowledge acquired by breast cancer specialists in a postgraduate course of Oncoplastic Surgery conducted in Santa Casa de Belo Horizonte (SCBH). Method: For this evaluation, an exploratory qualitative study was carried out. It was supported by an online survey questionnaire sent to 36 breast cancer specialists, who had taken the course in the period from 2012 to 2014. The data were interpreted using statistical methods, as well as probabilistic sampling. Results: After the Oncoplastic Surgery course, almost all breast cancer specialists who had taken it demonstrated the ability to reconstruct the breasts of women who had undergone mastectomies with oncoplastic techniques. A large portion of the specialists was able to develop bilateral treatment with breast reduction, mastopexy and rebuild areolas and nipples, as well as immediately reconstruct the breast with expanders or prosthesis and contralateral symmetrization. A significant amount of professionals was able to perform breast reconstruction with autologous flaps. Conclusion: The course for the Professional Development of Breast Cancer Specialists sponsored by the Teaching and Research Institute of Santa Casa de Belo Horizonte was able to improve the skills of the professionals involved in the different breast remodeling and reconstruction techniques. This enables a paradigm shift in the treatment of cancer patients.


Objetivo: Este trabalho objetiva investigar a eficácia e aprimoramento dos conhecimentos adquiridos por mastologistas no Curso de Pós-graduação de Oncoplastia Mamária da Santa Casa de Belo Horizonte (SCBH). Método: Para essa avaliação, realizou-se um estudo exploratório de natureza qualitativa. Como suporte, a aplicação de questionário de pesquisa, enviado online aos trinta e seis mastologistas que fizeram o Curso, no período de 2012 a 2014. Os dados foram interpretados por intermédio de métodos estatísticos, bem como por uma amostragem probabilística. Resultados: Após o Curso, quase a totalidade dos Mastologistas que se aprimoraram se mostram capazes de reconstruir a mama das mulheres mastectomizadas com técnicas oncoplásticas. Uma grande parcela tem condições de desenvolver tratamento bilateral com redução mamária, mastopexia e reconstruir aréolas e mamilos, e reconstruir de maneira imediata a mama, com expansores ou próteses e simetrização contralateral. Uma quantidade significativa dos profissionais é capaz de efetuar a reconstrução da mama com retalhos autólogos. Conclusão: O Curso promovido por esse Instituto de Ensino e Pesquisa foi capaz de aprimorar os profissionais envolvidos, nas diferentes técnicas de remodelamento e reconstrução mamária. Isso possibilita uma mudança de paradigma no tratamento da paciente oncológica.

16.
Mastology (Impr.) ; 27(2): [156-163], abr. - jun. 2017.
Artigo em Inglês | LILACS | ID: biblio-876398

RESUMO

Objective: The aims of this study were to determine the main managements of surgical complications in reconstructive mammoplasties with prostheses through a systematic literature review, and to evaluate the effectiveness in preserving the reconstruction. The secondary objective was to analyze factors regarding prosthetic loss. Methods: We used the MedLine database through the following expressions: "breast cancer" or "breast neoplasm" or "breast and neoplasm" or "breast and cancer" and "implants complications" or "implants and complications". The reference period for these studies comprised January 2000 to July 2016. Results: Of the 856 articles found, seven were included to analyze the applied protocols. The rate of saved prostheses after stratification of complications and use of managements varied from 45 to 100%, depending on the degree of complication. Other 12 articles that evaluated the factors associated with prosthetic loss were secondarily chosen. Radiotherapy was considered the most frequent factor and was found in seven studies. The number of lost prostheses varied from 0.9 to 22.7% in such studies. Conclusion: There is still no agreement on how to manage complications of reconstructive mammoplasties with prostheses. The decision remains a challenge, and therefore surgeons need to know the possible conducts in order to establish the most appropriate treatment.


Objetivos: O objetivo principal deste estudo foi determinar, por meio de revisão sistemática da literatura, as principais condutas nas complicações cirúrgicas de mastectomias reconstruídas com próteses, bem como avaliar a eficácia em preservar a reconstrução. O objetivo secundário foi analisar fatores relacionados à perda da prótese. Métodos: Foi empregado o banco de dados do MedLine, utilizando as expressões: breast cancer, ou breast neoplasm ou breast and neoplasm ou breast and cancer e implants complications ou implants and complications. O período de referência desses estudos foi de janeiro de 2000 até julho de 2016. Resultados: Dos 856 artigos encontrados, 7 foram incluídos para análise dos protocolos de condutas aplicados. A taxa de próteses salvas após estratificação das complicações e aplicação das condutas variou de 45 a 100%, a depender do grau de complexidade. Foram selecionados, secundariamente, outros 12 artigos que avaliaram fatores associados à perda da prótese. A mais frequente foi a radioterapia com 7 estudos. O número de próteses perdidas variou entre 0,9 e 22,7% nesses estudos. Conclusão: Ainda não existe unanimidade no manejo das complicações de mastectomias reconstruídas com próteses. Portanto, a decisão permanece desafiadora e o cirurgião necessita conhecer as possíveis condutas para definir a mais apropriada.

17.
Mastology (Impr.) ; 27(2): [135-143], abr. - jun. 2017.
Artigo em Inglês | LILACS | ID: biblio-876400

RESUMO

IIntroduction: Conserving surgery in the treatment of breast cancer, in association with radiotherapy, has replaced mastectomy in most cases. However, depending on the location and size of tumor, the classic conservative surgery can present unfavourable aesthetic results and high levels of commitment of the surgical margins. The oncoplastic breast surgery can have high local control rates and cause minimum breast deformities, leading to a better aesthetic result. Objective: To report cases of 30 patients with primary unilateral breast carcinoma who underwent oncoplastic surgery between 2013 and 2015. Methods: We used local and regional dermo-glandular rotation techniques. The average age of patients was 58.9 years. The average tumor size was 2.53 cm. Three patients had close or positive surgical margins and underwent a new surgical procedure. Results: The aesthetic result was evaluated by the BCCT.core program and was considered excellent in 11 cases, good in 12 cases and regular in 7 cases. Six patients had postoperative complications. Conclusion: The use of local and regional dermo-glandular rotation techniques allows extensive resections in breast conserving surgery, leading to a satisfying symmetry and a good aesthetic result without the need of symmetrization, with low postoperative complication rates and high rates of free surgical margins.


Introdução: A cirurgia conservadora no tratamento do câncer de mama, associada à radioterapia, tem substituído a mastectomia na maioria dos casos. Entretanto, dependendo da localização e do tamanho do tumor, a cirurgia conservadora clássica pode resultar em um resultado estético insatisfatório e em altos índices de comprometimento de margens cirúrgicas. A cirurgia oncoplástica da mama pode apresentar altas taxas de controle local, causando deformidades mamárias mínimas, levando a um melhor resultado estético. Objetivo: Relatar casos de 30 pacientes com carcinoma mamário unilateral que foram submetidas à cirurgia oncoplástica da mama entre 2013 e 2015. Métodos: Foram utilizadas técnicas de rotação dermoglandular local e regional. A idade média das pacientes foi de 58,9 anos. O tamanho médio do tumor foi 2,53 cm. Três pacientes apresentaram margens cirúrgicas exíguas ou comprometidas, sendo submetidas a novo procedimento cirúrgico. Resultados: O resultado estético foi avaliado pelo programa BCCT.core, sendo considerado excelente em 11 casos, bom em 12 casos e regular em 7 casos. Seis pacientes apresentaram complicações pós-operatórias. Conclusão: A utilização de técnicas de rotação dermoglandular local e regional permite ressecções extensas na cirurgia conservadora da mama, permitindo uma simetria satisfatória e um bom resultado estético sem a necessidade de simetrização, com baixos índices de complicação pós-operatória e altas taxas de margens cirúrgicas livres.

18.
Rev. bras. mastologia ; 26(4): 146-152, out.-dez. 2016. ilus
Artigo em Português | LILACS-Express | LILACS | ID: biblio-2680

RESUMO

A cirurgia oncoplástica e reconstrutiva da mama é parte importante do tratamento do câncer de mama, porém, faltam profissionais bem treinados e dedicados. Objetivo: Avaliar a eficácia do Programa de Educação Continuada Teórico-Prática em Oncoplastia e Reconstrução Mamária da Sociedade Brasileira de Mastologia no Hospital Araújo Jorge (HAJ), em Goiânia. Métodos: O programa foi divido em 10 módulos mensais de 24 horas, com 25% de teoria e 75% de cirurgias. As atividades foram coordenadas por dois professores locais e dois convidados. A avaliação do programa foi medida por meio de um questionário on-line respondido pelos alunos. A análise estatística foi realizada no SPSS®, sendo significativo um p<0,05. Resultados: Participaram como alunos 12 mastologistas, com 42,92 (±10,27) anos de média de idade. Foram realizados 213 procedimentos em 88 pacientes, abrangendo as principais técnicas de reconstrução mamária. Todos os alunos declararam-se satisfeitos e indicariam o curso a outros colegas. Ao início, a maioria dos alunos tinha apenas alguma experiência em reconstruções parciais com retalhos locais. Metade dos alunos referia dificuldades em conseguir outro colega que fizesse as reconstruções. Ao fim, a maioria dos alunos estava segura em realizar reconstruções parciais ou totais da mama, com retalhos locais, mamoplastias, lipoenxertia, expansores e próteses. A maioria estava segura para resolver suas complicações. Mais de um terço dos alunos estava seguro em realizar reconstruções com retalhos miocutâneos. Todos disseram estar interessados em continuar o aprimoramento técnico reconstrutivo de diferentes modos. Conclusão: O curso beneficiou as pacientes e contribuiu para a formação dos mastologistas participantes.


Oncoplastic and reconstructive surgery is an important part of the treatment of breast cancer. However,there is a lack of well trained and dedicated professionals. Objective: To evaluate the effectiveness of a Hands On Educational Program in Oncoplasty and Breast Reconstruction of the Brazilian Society of Mastology at the Hospital Araújo Jorge (HAJ), in Goiânia. Methods: The program was divided into 10 monthly 24-hour modules, with 25% of theory and 75% of surgery. Activities were coordinated by two local and two invited teachers. The effectiveness was measured via an on-line questionnaire. Statistical analysis was performed by SPSS®. It was significant a p<0.05. Results: Twelve mastologists participated, with a mean age of 42.92 (±10.27). They performed 213 procedures in 88 patients, using the main techniques for breast reconstruction. All students declared themselves satisfied with the course and they would indicate it to others. At the beginning, most students had some experience in local flaps. Half of the students referred trouble in finding other colleagues that could perform the reconstructions. At the end, most students declared themselves comfortable to perform partial or total reconstruction of the breast with local flaps, mammaplasties, fat grafting, expanders and implants. Most of them were comfortable to resolve their own complications. More than a third was safe in performing miocutaneous flaps. All mastologists said to be interested in continuing technical improvement in different ways. Conclusion: The current program in Goiânia benefited many patients and brought a great contribution to the training of the participants.

19.
Rev. bras. mastologia ; 26(4): 153-157, out.-dez. 2016. ilus, tab
Artigo em Português | LILACS-Express | LILACS | ID: biblio-2681

RESUMO

Objetivo: Avaliar a expressão transcricional do gene LEP que codifica a leptina, na tentativa de elucidar o mecanismo de aumento da expressão plasmática descrito na literatura. Métodos: Foram utilizadas 26 amostras de tecido mamário, das quais 13 são tumorais e 13 não tumorais (provenientes da mama contralateral ao câncer), e foram realizadas análises da expressão gênica por meio da reação em cadeia de polimerase em tempo real. Resultados: A análise mostrou uma expressão 8,67 vezes superior no tecido não tumoral, não demonstrando correspondência com os dados da literatura. Os dados gerados foram analisados em relação ao receptor hormonal, ao tipo e tamanho tumoral e à idade das pacientes (pré­ e pós­menopausa), as quais, neste último, tive­ ram uma tendência à maior expressão de leptina no tecido tumoral. Conclusão: Uma ampliação da amostra e dos dados de correlação, como a presença ou ausência de obesidade, é necessária para melhores conclusões, mas os dados iniciais sugerem que possa existir uma forte regulação pós­transcricional no tecido não tumoral.


Objective: To evaluate the transcriptional expression of the LEP gene that encodes leptin in an attempt to elucidate the increased plasma expression mechanism described in literature. Methods: Twenty­six samples of mammary tissue were used, in which 13 are tumoral and 13 are non­tumoral samples from the contralateral breast during cancer. Gene expression analyses were performed by re­ al­time polymerase chain reaction. Results: The analysis showed an 8.67 higher expression in non­tu­ moral tissue, therefore it did not demonstrate a correspondence with literature data. The generated data were further analyzed for hormone receptor, tumor type and size, and age of patients (before and after menopause), and the latter demonstrated a trend to higher leptin expression in the tumoral tissue. Conclusion: A larger sample and correlation data, like the presence or absence of obesity, is needed for better conclusions, but these initial data suggest that there may be a strong post­transcriptional regulation in non­tumoral tissue.

20.
PLoS One ; 11(1): e0145647, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26751376

RESUMO

MTAP is a ubiquitously expressed gene important for adenine and methionine salvage. The gene is located at 9p21, a chromosome region often deleted in breast carcinomas, similar to CDKN2A, a recognized tumor suppressor gene. Several research groups have shown that MTAP acts as a tumor suppressor, and some therapeutic approaches were proposed based on a tumors´ MTAP status. We analyzed MTAP and CDKN2A gene (RT-qPCR) and protein (western-blotting) expression in seven breast cancer cell lines and evaluated their promoter methylation patterns to better characterize the contribution of these genes to breast cancer. Cytotoxicity assays with inhibitors of de novo adenine synthesis (5-FU, AZA and MTX) after MTAP gene knockdown showed an increased sensitivity, mainly to 5-FU. MTAP expression was also evaluated in two groups of samples from breast cancer patients, fresh tumors and paired normal breast tissue, and from formalin-fixed paraffin embedded (FFPE) core breast cancer samples diagnosed as Luminal-A tumors and triple negative breast tumors (TNBC). The difference of MTAP expression between fresh tumors and normal tissues was not statistically significant. However, MTAP expression was significantly higher in Luminal-A breast tumors than in TNBC, suggesting the lack of expression in more aggressive breast tumors and the possibility of using the new approaches based on MTAP status in TNBC.


Assuntos
Adenocarcinoma Mucinoso/genética , Carcinoma Ductal de Mama/genética , Carcinoma Lobular/genética , Inibidor p16 de Quinase Dependente de Ciclina/genética , Regulação Neoplásica da Expressão Gênica , Purina-Núcleosídeo Fosforilase/genética , Neoplasias de Mama Triplo Negativas/genética , Adenocarcinoma Mucinoso/tratamento farmacológico , Adenocarcinoma Mucinoso/metabolismo , Adenocarcinoma Mucinoso/patologia , Antineoplásicos/farmacologia , Azacitidina/farmacologia , Carcinoma Ductal de Mama/tratamento farmacológico , Carcinoma Ductal de Mama/metabolismo , Carcinoma Ductal de Mama/patologia , Carcinoma Lobular/tratamento farmacológico , Carcinoma Lobular/metabolismo , Carcinoma Lobular/patologia , Linhagem Celular Tumoral , Inibidor p16 de Quinase Dependente de Ciclina/metabolismo , Metilação de DNA , Receptor alfa de Estrogênio/deficiência , Receptor alfa de Estrogênio/genética , Feminino , Fluoruracila/farmacologia , Humanos , Metástase Linfática , Metotrexato/farmacologia , Especificidade de Órgãos , Regiões Promotoras Genéticas , Purina-Núcleosídeo Fosforilase/antagonistas & inibidores , Purina-Núcleosídeo Fosforilase/metabolismo , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/metabolismo , Receptor ErbB-2/deficiência , Receptor ErbB-2/genética , Receptores de Progesterona/deficiência , Receptores de Progesterona/genética , Transdução de Sinais , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Neoplasias de Mama Triplo Negativas/metabolismo , Neoplasias de Mama Triplo Negativas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...